On the 4th, Acepodia-KY announced a strategic partnership with global biotech leader Pfizer. Through the extensive resources and expert support provided by Pfizer's Ignite program, Acepodia aims to accelerate the development of its breakthrough immunotherapies, offering new treatment hope for cancer and immune disease patients.

Pfizer Ignite is a biotechnology collaboration initiative that focuses on driving innovative treatments in partnership with biotech companies, particularly in the fields of oncology, inflammation and immunology, cardiovascular/respiratory diseases, and hematological disorders. The program offers tailored services and technical support, including expert consultation, research, and manufacturing capabilities, encouraging biotech companies to independently innovate and expedite the drug development process.

Acepodia noted that becoming a Pfizer Ignite partner allows the company to benefit from Pfizer's rich resources, expertise, and R&D capabilities across multiple stages, including preclinical research, clinical trial design, and regulatory strategies. This partnership will significantly enhance the speed and effectiveness of developing innovative drugs.

CEO Sonny Hsiao expressed that Pfizer's extensive experience and robust resources are crucial for advancing Acepodia’s clinical projects. The collaboration is expected to greatly accelerate the development of Acepodia’s innovative immunotherapies, bringing transformative treatments to cancer and immune disease patients who are in urgent need of new therapies.

Dr. Kathy Fernando, Senior Vice President and Head of Pfizer Ignite, also expressed high expectations for the partnership. She highlighted that after an internal evaluation by the Pfizer team, Acepodia’s innovative immunotherapy approach aligns closely with Pfizer’s mission to support breakthrough technologies. She is hopeful that this collaboration will accelerate the development of Acepodia’s cell therapies, ultimately benefiting more patients in need of treatment.

Industry experts believe that with Pfizer’s strong resources and professional support, combined with Acepodia’s technological advantages in the field of immunotherapy, this strategic partnership will undoubtedly inject new energy into cancer treatment.

Resource (mandarin): 育世博、輝瑞戰略合作 加速開發創新免疫療